Invivyd Logo
HARNESSING A NOVEL APPROACH

Scientific publications and presentations

Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19The New England Journal of Medicine
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialCameron R. Wolfe et al. medRxiv.
Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineageColin Powers et al. bioRxiv.
Results from a Phase 1 First-in-human Study of Pemivibart: an Extended–half-life Monoclonal AntibodyHolmes et al. IDWeek. 2024.
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following the Second Dose of Pemivibart in the Phase 3 CANOPY TrialHolmes et al. IDWeek. 2024.
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating Pemivibart for the Prevention of COVID-19Popejoy et al. IDWeek. 2024.
Preliminary results for solid organ transplant patients enrolled in CANOPY, a phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for prevention of COVID-19.Popejoy et al. ATC. 2024.
A phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for prevention of COVID-19 (CANOPY): Subset analysis of participants with significant immune compromise in the setting of solid tumor or hematologic malignancies.Popejoy et al. ASCO. 2024.
Population pharmacokinetics of pemivibart (VYD222), an extended–half-life monoclonal antibody in development for the pre-exposure prophylaxis of COVID-19Rubino et al. MAD-ID. 2024.
Six-month interim analysis from a phase 1 first-in-human study of pemivibart: an extended half-life monoclonal antibody (mAb) authorized for pre-exposure prophylaxis for COVID-19 in certain adults and adolescents with moderate to severe immune compromise.Mahoney et al. MAD-ID. 2024.
In vitro neutralisation of pemivibart (VYD222) against Omicron sublineages.West et al. ECCMID. 2024.
Preliminary safety results from a phase 1 first in human study of VYD222: an extended half-life monoclonal antibody (mAb) in development for COVID-19 prevention.Mahoney et al. IDWeek. 2023.
Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a phase 2/3 randomized, double-blind, placebo-controlled trial (EVADE).Ison et al. Open Forum Infectious Diseases. 2023.
Efficacy and safety of adintrevimab (ADG20) for the treatment of high-risk ambulatory patients with mild or moderate COVID-19: results from a phase 2/3, randomized, placebo-controlled trial (STAMP) conducted during Delta predominance and early emergence of Omicron.Ison et al. Open Forum Infectious Diseases. 2023.

Older publications and presentations

Assessment of effect of adintrevimab on COVID-19 vaccine response.Tosh et al. ISIRV-AVG. 2023.
NVD200 potently neutralizes Omicron and its sublineages.West et al. ECCMID. 2023.
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.Schmidt et al. Science Translational Medicine. 2023.
ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants.Kaku et al. ECCMID. 2022.
Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.Rubino et al. ECCMID. 2022.
Results from the phase 2/3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of adintrevimab (ADG20) in the treatment of ambulatory participants with mild or moderate COVID-19 (STAMP).Popejoy et al. ASM Microbe. 2022.
Broad and potent in vitro neutralization of SARS-CoV-2 variants by ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19.Kaku et al. ISIRV-WHO. 2021.
Evaluating the safety, tolerability, and pharmacokinetics of ADG20, a half-life–extended monoclonal antibody (mAb) in development for the prevention and treatment of COVID-19: a preliminary analysis of a randomized phase 1 study.Schmidt et al. ISIRV-WHO. 2021.
A whole-body quantitative system pharmacology physiologically based pharmacokinetic model that a priori predicts pharmacokinetics of ADG20: an extended half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.Van Wart et al. ID Week. 2021.
A whole-body quantitative system pharmacology physiologically based pharmacokinetic model to support dose selection of ADG20: an extended half-life monoclonal antibody being developed for the treatment of coronavirus disease (COVID-19).Tarbell et al. ID Week. 2021.
Use of a whole-body quantitative system pharmacology physiologically based pharmacokinetic model to support ADG20 dose selection for the prevention of coronavirus disease (COVID-19).Van Wart et al. ID Week. 2021.
Preliminary results from a phase 1 single ascending-dose study assessing safety, pharmacokinetic profile, and serum viral neutralizing antibody titers of ADG20: an extended half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.Paguntalan et al. ID Week. 2021.
The ADG20 human monoclonal antibody binds with high affinity and neutralises a wide range of SARS-CoV-2 variants and zoonotic Sarbecoviruses.Kaku et al. ECCMID. 2021.
Prophylactic administration of the monoclonal antibody ADG20 provides potent protection against SARS-CoV-2 in rodent and non-human primate models of COVID-19.Narayan et al. ECCMID. 2021.
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.Rappazzo et al. Science. 2021.
An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19.Rappazzo et al. bioRxiv. 2020.
Broad neutralization of SARS-related antibodies by human monoclonal antibodies.Wec et al. Science. 2020.

The information on this website is intended to provide scientific information about Invivyd research for healthcare providers. Information may include data on investigational products or investigational uses of approved or authorized products for which safety and effectiveness have not been established. There is no guarantee that such products or uses will receive health authority approval, and Invivyd does not recommend or suggest use of its medicines in a manner inconsistent with approved or authorized labeling. This section includes selected Invivyd abstracts, posters or oral presentations.